Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.

Abstract

This randomized, double-blind study compared the efficacy and safety of blonanserin and risperidone to treat Chinese schizophrenia patients aged ≥18 and < 65 years. Patients with Positive and Negative Syndrome Scale (PANSS) total scores ≥70 and ≤ 120 were randomized to receive blonanserin or risperidone using a gradual dose-titration method (blonanserin tablets: 8-24 mg/day; risperidone tablets: 2-6 mg/day), twice daily. Treatment populations consisted of 128 blonanserin-treated patients and 133 risperidone-treated patients. Intention-to-treat analysis was performed using the last observation carried forward method. Reductions of PANSS total scores by blonanserin and risperidone treatment were -30.59 and -33.56, respectively. Risperidone treatment was associated with elevated levels of serum prolactin (67.16% risperidone versus 52.31% blonanserin) and cardiac-related abnormalities (22.39% risperidone versus 12.31% blonanserin), and blonanserin patients were more prone to extrapyramidal side effects (48.46% blonanserin versus 29.10% risperidone). In conclusion, blonanserin was as effective as risperidone for the treatment of Chinese patients with schizophrenia. The overall safety profiles of these drugs are comparable, although blonanserin was associated with a higher incidence of EPS and risperidone was associated with a higher incidence of prolactin elevation and weight gain. Thus, blonanserin is useful for the treatment of Chinese schizophrenia patients.

• Authors: Huafang Li, Chen Yao, Jianguo Shi, Fude Yang, Shuguang Qi, Lili Wang, Honggeng Zhang, Jie Li, Chuanyue Wang, Chuansheng Wang, Cui Liu, Lehua Li, Qiang Wang, Keqing Li, Xiaoyan Luo, Niufan Gu
• Journal: Journal of psychiatric research (J Psychiatr Res) Vol. 69 Pg. 102-9 (Oct 2015) ISSN: 1879-1379 [Electronic] England
• PMID: 26343601 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Chemical References

• Antipsychotic Agents
• Piperazines
• Piperidines
• Prolactin
• blonanserin
• Risperidone

Topics

• Adolescent
• Adult
• Aged
• Antipsychotic Agents (administration & dosage, adverse effects)
• Asian People
• China
• Double-Blind Method
• Drug Administration Schedule
• Female
• Humans
• Male
• Middle Aged
• Piperazines (administration & dosage, adverse effects)
• Piperidines (administration & dosage, adverse effects)
• Prolactin (blood)
• Psychiatric Status Rating Scales
• Risperidone (administration & dosage, adverse effects)
• Schizophrenia (drug therapy, ethnology, physiopathology)
• Schizophrenic Psychology
• Treatment Outcome
• Weight Gain (drug effects)
• Young Adult